Evotec 566480, wohin geht die Reise??? (Seite 6669)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 11.05.24 11:52:35 von
neuester Beitrag 11.05.24 11:52:35 von
Beiträge: 82.084
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 236
Gesamt: 16.241.455
Gesamt: 16.241.455
Aktive User: 1
ISIN: DE0005664809 · WKN: 566480
9,5525
EUR
+0,10 %
+0,0100 EUR
Letzter Kurs 07:26:14 Lang & Schwarz
Neuigkeiten
Evotec Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
04:45 Uhr · inv3st.de Anzeige |
12.05.24 · wO Chartvergleich |
11.05.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
8,8800 | +57,45 | |
17,440 | +44,61 | |
1,8400 | +26,03 | |
4,9500 | +25,32 | |
4,0000 | +25,00 |
Wertpapier | Kurs | Perf. % |
---|---|---|
10,965 | -18,48 | |
0,7845 | -19,36 | |
3,3200 | -22,61 | |
0,6785 | -26,19 | |
3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 41.359.339 von ciel34 am 13.04.11 10:08:44besser folgende Quelle:
http://www.evotec.com/uploads/cms_article/192/Commerzbank_20…
Grüße
http://www.evotec.com/uploads/cms_article/192/Commerzbank_20…
Grüße
Antwort auf Beitrag Nr.: 41.358.958 von bruder_halblang am 13.04.11 09:21:37Eine Kaufempfehlung der Commerzbank mit Ziel 4,15 ist der Grund des Anstiegs.
Quelle?
Quelle?
Ach, was lese ich gerade: Eine Kaufempfehlung der Commerzbank mit Ziel 4,15 ist der Grund des Anstiegs. Schade, denn ein Anstieg ohne ersichtlichen Grund wäre mir lieber gewesen (siehe oben). Hoffentlich verpufft dieser Anstieg nicht auch wieder im Sumpf das schwierigen Börsenjahres 2011!
So richtig klar ist mir der Grund des Kursanstiegs nicht. Aber vielleicht führt dieser Umstand gerade dazu, dass der Verkaufsdruck nachlässt, dass sich also keiner mehr traut, Evotec zu verkaufen. Denn wenn der Aktienkurs schon ohne ersichtlichen Grund zulegt ...
Antwort auf Beitrag Nr.: 41.358.735 von Ackergaul am 13.04.11 08:47:58und schon eine Reaktion darauf. Kurs eröffnet mit fast 4% 3,14 €
http://www.outsourcing-pharma.com/content/view/print/369136
Outsourcing penetration set for double-digit
growth in ‘11
By Nick Taylor, 12-Apr-2011
Related topics: Phase I-II, Phase III-IV, Preclinical, Clinical Development, Globalisation, Clinical evolution
Outsourcing penetration growth will hit double-digits, above analyst expectations, in 2011
and offset flat R&D budgets, found an RW Baird survey.
Respondents from biopharm of all sizes said the percentage of research and development (R&D) budget
outsourced will rise in 2011. Overall penetration is predicted to reach 41 per cent in 2011, with small
firms outsourcing more, and this figure could increase significantly in coming years.
“We have believed that the ultimate end game is for outsourcing penetration to at least hit 60 per cent,
and possibly 80 per cent, in the distant future”, said Eric Coldwell, managing director, healthcare equity
research at RW Baird. Some believe penetration could go even higher.
To reach the upper end of these predictions outsourcing must continue to evolve and mature. As it
stands, even the largest outsourcing deals are yet to “scratch the surface of what pharmas could do to
change the game”, said Coldwell.
Evolution of, and beyond, strategic partnerships is needed. Coldwell said: “The real key to making
strategic alliances powerful will be when we see CROs’ scientific involvement increasing and when
pharmas relinquish their patriarchal control of vendor process.”
Growing outsourcing penetration through closer relationships will help CROs offset flat R&D budgets.
Predictions for R&D spend in coming years vary, a little, by geography and company size but overall
growth is expected to be modest, beginning with a one per cent rise in 2011.
Pricing surprise
Outsourcing penetration growth predictions were a few percentage points above, but broadly in-line
with, RW Baird expectations. A more surprising finding, and the only one that went against
expectations, related to change in CRO pricing over the past three months.
Price increases were reported by 35 per cent of respondents. Aggregating and averaging all data, across
company size and developmental stage, a mid-single digit increase in outsourcing price was reported.
“We are shocked by this pricing feedback”, said Coldwell. RW Baird, and other observers, believed client
cost management, volume discounts and excess capacity are still a drag on CRO pricing.
If accurate the finding would be a “big positive” for CROs and see performance beat expectations in
2011. However, while it “appears to be more than a statistical anomaly”, more work is needed to
confirm the finding.
China, clinical, oncology
Other findings were much closer to expectations. The survey asked respondents how and where they
would invest if they ran a global CRO. Overwhelmingly, China was the most selected country, clinical the
most popular R&D phase, and oncology the therapeutic area of choice.
CROs with strength in these areas are positioned to prosper in coming years. “We believe that CROs
which have greater scale and scope in Asia, Central and Eastern Europe and the US will outperform
those with a larger presence in the UK or Western Europe”, said Coldwell.
Ich denke die Aussichten für Evotec in den kommenden Jahren sind mehr als ausgezeichnet.
Grüße
Outsourcing penetration set for double-digit
growth in ‘11
By Nick Taylor, 12-Apr-2011
Related topics: Phase I-II, Phase III-IV, Preclinical, Clinical Development, Globalisation, Clinical evolution
Outsourcing penetration growth will hit double-digits, above analyst expectations, in 2011
and offset flat R&D budgets, found an RW Baird survey.
Respondents from biopharm of all sizes said the percentage of research and development (R&D) budget
outsourced will rise in 2011. Overall penetration is predicted to reach 41 per cent in 2011, with small
firms outsourcing more, and this figure could increase significantly in coming years.
“We have believed that the ultimate end game is for outsourcing penetration to at least hit 60 per cent,
and possibly 80 per cent, in the distant future”, said Eric Coldwell, managing director, healthcare equity
research at RW Baird. Some believe penetration could go even higher.
To reach the upper end of these predictions outsourcing must continue to evolve and mature. As it
stands, even the largest outsourcing deals are yet to “scratch the surface of what pharmas could do to
change the game”, said Coldwell.
Evolution of, and beyond, strategic partnerships is needed. Coldwell said: “The real key to making
strategic alliances powerful will be when we see CROs’ scientific involvement increasing and when
pharmas relinquish their patriarchal control of vendor process.”
Growing outsourcing penetration through closer relationships will help CROs offset flat R&D budgets.
Predictions for R&D spend in coming years vary, a little, by geography and company size but overall
growth is expected to be modest, beginning with a one per cent rise in 2011.
Pricing surprise
Outsourcing penetration growth predictions were a few percentage points above, but broadly in-line
with, RW Baird expectations. A more surprising finding, and the only one that went against
expectations, related to change in CRO pricing over the past three months.
Price increases were reported by 35 per cent of respondents. Aggregating and averaging all data, across
company size and developmental stage, a mid-single digit increase in outsourcing price was reported.
“We are shocked by this pricing feedback”, said Coldwell. RW Baird, and other observers, believed client
cost management, volume discounts and excess capacity are still a drag on CRO pricing.
If accurate the finding would be a “big positive” for CROs and see performance beat expectations in
2011. However, while it “appears to be more than a statistical anomaly”, more work is needed to
confirm the finding.
China, clinical, oncology
Other findings were much closer to expectations. The survey asked respondents how and where they
would invest if they ran a global CRO. Overwhelmingly, China was the most selected country, clinical the
most popular R&D phase, and oncology the therapeutic area of choice.
CROs with strength in these areas are positioned to prosper in coming years. “We believe that CROs
which have greater scale and scope in Asia, Central and Eastern Europe and the US will outperform
those with a larger presence in the UK or Western Europe”, said Coldwell.
Ich denke die Aussichten für Evotec in den kommenden Jahren sind mehr als ausgezeichnet.
Grüße
UI, was geht ab? Da hat jemand 40k Stück in Stuttgart gekauft..... zu 3,12....
Zitat von bioudo: ;-), hätte besser nichts vom Markt gesagt.
Jetzt geht auch unsere Evotec runter ;-(
na und! sind doch nur paar Cent. Das bedeutet doch nichts.
hier eine Nachricht :
Biotech – Aktientipp Evotec aus diesem Grund jetzt beachten!
Liebe Leser,
das Biotechunternehmen schreibt erstmals schwarze Zahlen in der bereits langen Firmengeschichte.
Im Jahr 2010 blieben rund 3 Millionen Euro hängen. Die Umsätze kletterten um 29 Prozent auf 55,3 Millionen Euro. Das Unternehmen hat die eigenen Entwicklungsprojekte zurückgestellt. Evotec legt den Fokus auf Forschungsallianzen. Die Kosten dafür tragen die Auftraggeber.
Im laufenden Geschäftsjahr will der Vorstandschef mindestens zwei große neue Deals an Land ziehen. Im Jahr 2010 war dasselbe Ziel geplant, jedoch nur vier Verträge erreicht. Da das Unternehmen zunehmend an die Kapazitätsgrenze stößt, dürften die Ziele 2011 weniger deutlich übertroffen werden. Eine Partnerschaft könnte noch im ersten Halbjahr 2011 für Auftrieb beim Aktienkurs sorgen.
Ein Umsatzwachstum von mindestens 15 Prozent ist in diesem und auch in den nächsten Jahren auf jeden Fall geplant.
aus:
http://www.moneymoney.de/201104125069/moneymoney/boersen-blo…
lassen wir uns überraschen!
04:45 Uhr · inv3st.de · BayerAnzeige |
12.05.24 · wO Chartvergleich · Carl Zeiss Meditec |
11.05.24 · wO Chartvergleich · American Express |
10.05.24 · Sharedeals · Evotec |
09.05.24 · Sharedeals · Evotec |
09.05.24 · wallstreetONLINE Redaktion · Bayer |
09.05.24 · kapitalerhoehungen.de · Bayer |
08.05.24 · wallstreetONLINE Redaktion · Evotec |